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Systematic reviews and meta-analyses of randomized trials that include patient-reported outcomes (PROs) often
provide crucial information for patients and clinicians facing challenging health care decisions. Based on emerging
methods, guidance on combining PROs in meta-analysis is likely to enhance their usefulness.
The objectives of this paper are: i) to describe PROs and why they are important for health care decision-making,
ii) illustrate the key risk of bias issues that systematic reviewers should consider and, iii) address outcome
characteristics of PROs and provide guidance for combining outcomes.
We suggest a step-by-step approach to addressing issues of PROs in meta-analyses. Systematic reviewers should
begin by asking themselves if trials have addressed all the important effects of treatment on patients’ quality of life.
If the trials have addressed PROs, have investigators chosen the appropriate instruments? In particular, does
evidence suggest the PROs used are valid and responsive, and is the review free of outcome reporting bias?
Systematic reviewers must then decide how to categorize PROs and when to pool results.
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decision-makingIntroduction
Systematic reviews and meta-analyses of randomized
control trials (RCTs) often include patient-reported out-
comes (PROs). Including PROs is likely to be accompan-
ied by issues of validity (can we trust the methods) and
interpretability (what do the results mean), about which
many systematic review authors are uncertain. The pur-
pose of this article (Part 1) and a subsequent companion
article (Part 2) is to familiarize systematic review authors
with the nature of PROs and to provide guidance in ne-
gotiating the sometimes complex issues that they raise.
Our discussion should be of interest to authors of system-
atic reviews and clinical practice guidelines, and other
decision-makers wishing to take a critical perspective on* Correspondence: bradley.johnston@sickkids.ca
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reproduction in any medium, provided the orhow reviews have addressed issues of risk of bias and ana-
lysis of PROs. Much of the methodology laid out in this
paper is also relevant to proxy-reported outcomes.
Clinical trials evaluating medical treatments and health
interventions increasingly incorporate self-reported mea-
sures from patients, often referred to as PROs.
According to the US Food & Drug Administration
(FDA) Guidance for Industry - Patient-Reported Out-
come Measures: a PRO is “any report of the status of a
patient’s health condition that comes directly from the
patient without interpretation of the patient’s response
by a clinician or anyone else”. It can be measured in ab-
solute terms (e.g., severity of a sign, symptom or state of
a disease) or as a change from a previous measure [1].Why patient-reported outcomes?
PROs provide patients’ perspective on treatment benefit,
directly measure treatment benefit beyond survival and
major morbid events, and are often the outcomes of
most significance to patients. Investigators sometimesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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complement primary outcomes measured by survival, or
major morbid events (e.g. stroke, myocardial infarction,
disease exacerbation). Investigators also sometimes focus
on biomarkers involving physiological, biological or
laboratory-based measures (blood and tissue) or
clinician-reported outcomes from various types of tests
(biomarkers, physical examination), but these can only
provide indirect evidence regarding patient-important
outcomes [2]. Figure 1 provides examples of different
outcomes that may be captured in clinical trials, includ-
ing PROs.
Reports from patients may include sensations (most
commonly classified as symptoms both of disease and
treatment, sometimes referred to as side-effects), behav-
iours and abilities (most commonly classified as func-
tional status), general perceptions or feelings of well-





















Figure 1 Sources and examples of patient outcomes.of life (HRQoL), reports of adverse effects and adherence
to treatment. PROs can be captured through interviews,
self-completed questionnaires, diaries or other data col-
lection tools such as hand-held devices and web-based
forms. Although investigators may address these out-
comes via proxy reports from caregivers, health profes-
sionals, or parents and guardians, these are not PROs.
Self-report measures often correlate poorly with
physiologic measures. In asthma, Yohannes et al. found
that variability in exercise capacity contributed to only
3% of the variability on a patient self-report question-
naire (the Breathing Problems Questionnaire; BPQ) [3].
In Chronic Obstructive Pulmonary Disease, the reported
correlations between forced expiratory volume (FEV1)
and HRQoL are relatively weak (r = 0.14 to 0.41) [4].
Similarly, in Peripheral Arterial Occlusive Disease, corre-
lations between haemodynamic parameters and HRQoL
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reported pain [7]. These findings emphasize the limited
value of surrogates for informing us about the impact of
interventions on patient-important outcomes.
PROs are key measures of treatment outcomes in some
disease areas
PROs are most important when externally observable
patient-important outcomes are unavailable, likely to
be biased, or are rare. For many conditions, including
pain syndromes, functional disorders, sexual dysfunc-
tion, emotional function and insomnia, PROs provide
the only reasonable strategy for evaluating treatment
impact.
Caregiver observed outcomes may be necessary in
some conditions, such as advanced cancer and cognitive
impairment, but PROs should be used whenever pos-
sible. The patient’s point of view should be of intrinsic
interest to all stakeholders engaged in the area of health
and illness. The ‘Checklist for describing and assessing
PROs in clinical trials’ presents selected issues that au-
thors should consider when reporting PROs in their
reviews.
Checklist for describing and assessing PROs in clinical
trials [8].
1. What were the PROs measuring?
1.1.What concepts or constructs were the PROs
used in the study measuring?
1.2.What rationale (if any) for selection of concepts
or constructs did the authors provide?
1.3.Were patients involved in the selection (e.g.
focus groups, surveys) of PROs?
2. Omissions
2.1.Were there any important aspects of patient’s
health (e.g., symptoms, function, perceptions) or
quality of life (e.g. overall evaluation, satisfaction
with life) that were not reported in this study?
3. If RCTs measured PROs, what were the instruments
measurement strategies?
3.1.Did investigators use instruments that yield a
single indicator or index number, a profile, or a
battery of instruments?
3.2.If investigators measure PROs, did they use
specific or generic measures, or both?
4. Did the instruments work in the way they were
supposed to work – validity?
4.1.Was evidence of prior validation for use in the
current population presented?
4.2.Were the instruments re-validated in this study?
5. Did the instruments work in the way they were
supposed to work – ability to measure change?
5.1.Are the PROs able to detect change in patient
status, even if those changes are small?6. Can you make the magnitude of effect (if any)
understandable to readers?
6.1.Can you provide an estimate of the difference in
patients achieving a threshold of function or
improvement, and the associated number needed
to treat (NNT)?
*Based on Chapter 7 of Health Status and Health
Policy, Guyatt et al, Users’ Guides to the Medical
Literature: XII. How to Use Articles About
Health-related quality of life.Description of PROs
Reviewers should understand the nature of the PROs
used in each study, and communicate this information
to the reader. Many different ways exist to label and
classify patient outcomes, some of which are presented
in Figure 1.
Health status and quality of life outcomes are an im-
portant category of PROs. Published papers often use
the terms ‘quality of life’ (QoL), ‘health status’, ‘functional
status’, ‘health-related quality of life’ (HRQoL) and ‘well-
being’ loosely and interchangeably (see Table 1). For ex-
ample, the meaning of QoL or HRQoL varies widely,
ranging from psychosocial or patient-reported measures
including those with limited evidence of validity, to well
validated disease specific or generic HRQoL measures.
The constructs captured in RCT outcomes can only
be determined by examining the actual content of items
or questions included in an instrument claiming to
measure QoL or HRQoL. The labeling of concepts varies
widely among researchers and few conventions apply.
For example, an item measuring pain, a sensation known
only to the patient, would be a symptom, or an aspect of
QoL. Nonetheless, each item, subdomain, domain, or
overall score addresses one or more concepts, which can
be identified from the content (e.g. actual terminology
used in the item).
Guidance from the GRADE working group is relevant
to optimal approaches to using PROs in systematic re-
views. GRADE is a system of rating confidence in esti-
mates of effect (quality of evidence) that is extensively
used and widely endorsed, including by the Cochrane
Collaboration [9,10]. Using the GRADE process, the
final product of a systematic review is an Evidence Pro-
file or a Summary of Findings table (SoF) that presents,
for each relevant comparison of alternative management
strategies, the confidence in estimates for each outcome
and, for dichotomous outcomes the best estimate of the
magnitude of effect in relative terms and the absolute ef-
fect that one might see across sub-groups of patients
with varying baseline or control group risks.
Currently, many primary studies do not seem to meas-
ure aspects of perceived health and QoL that are import-
ant to patients. A recent systematic review examining
Table 1 Definitions of selected terms related to PROs
Condition-specific Measure or
Instrument
A category of health measures that describes problems such as low-back pain or particular interventions or
treatments such as knee-replacement or coronary artery bypass graft surgery.
Disease-Specific Measure or
Instrument
A category of health measures of severity, symptoms, or functional limitations that are specific to a particular
disease state, condition, or diagnostic grouping; for example, arthritis or diabetes.
Domain (also known as
dimension)
PROs often have domains or dimensions as subcategories. For instance, the SF-36, a very popular instrument, has
8 domains or dimensions. Examples of domains defined for the SF-36 include: physical role functioning, social
role functioning, emotional role functioning, and mental health. An alternative, less satisfactory designation is
“subscale”.
Functional Status An individual’s effective performance or ability to perform those roles, tasks, or activities that are valued, e.g.
going to work, playing sports, or maintaining the house. Most often, functional status is divided into physical,
emotional, mental, and social domains, although much finer distinctions are possible. Deviations from usual
performance or ability indicate dysfunction.
Generic Measure A measure designed for use with any illness groups or population samples, as opposed to those intended for
specific illness groups.
Health-Related Quality of Life Personal health status. It usually refers to aspects of our lives that are dominated or significantly influenced by
our mental or physical well-being.
Patient Satisfaction A consequence of the use of healthcare products, services or programs that affect patients’ satisfaction with
health or healthcare.
Quality of life An evaluation of all aspects of our lives, including, for example, where we live, how we live, and how we play. It
encompasses such life factors as family circumstances, finances, housing and job satisfaction.
Self-reported Symptoms Symptoms, which are directly reported by the patient by means of questionnaires, diaries, hand held devices or
web-based forms.
Well-Being Subjective bodily and emotional states; how an individual feels; a state of mind distinct from functioning that
pertains to behaviours and activities.
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PROs in contemporary cardiovascular disease RCTs sup-
ports this notion: only 93 of 413 (23%) RCTs included
patient-important outcomes as their primary measures.
The study reported 122 of 174 (70%) RCTs where such
outcomes would have been important or crucial excluded
such outcomes, emphasizing the underuse of PROs with
consideration to their relevance and importance to clinical
decision-making [11]. One of the recommendations from
GRADE and from the GRADE-associated Cochrane Ap-
plicability and Recommendations Methods group is that
reviewers should begin the review process by defining and
listing all patient-important outcomes [10,12] that are
relevant to their question, which will include PROs.
Patient-important outcomes often include morbidity, mor-
tality, adverse events, hospitalization, function, disability,
QoL, and inconvenience. Lacking evidence for important
outcomes should be acknowledged rather than ignored to
account for uncertainty surrounding reported results and
clinical decision-making. This step is germane to the
measurement of PROs. If primary studies fail to measure
important aspects of patient perceptions, we may be much
less confident regarding the treatment impact on PROs
than we are about other outcomes. All patient-important
outcomes should be included in a SoF table. In the ex-
treme, there may be a line in the SoF table that is blank,
because no study addressed this issue directly (and that
blank line may refer to an important PRO). The careful
prior consideration of all patient-important outcomes willhighlight what is missing in outcomes reported in eligible
RCTs.
If primary studies eligible for a systematic review have
used PROs, it is worth considering the measurement
strategies those PROs employed. Investigators may
choose a single instrument that yields an overall score or
indicator number (representing the impact of the inter-
vention on mental or emotional function such as the
Hospital Anxiety and Depression Scale), a health utility
index number (again an overall score, but weighted in
terms of anchors of death and full health), a profile (a
series of scores, one for each dimension or domain), or a
battery of tests (multiple PROs assessing different con-
cepts or constructs) (Table 2).
If they have focused on HRQoL, trialists will have
chosen generic or specific instruments, or a combin-
ation. If investigators were interested in going beyond
the specific illness and possibly making comparisons be-
tween the impact of treatments on HRQoL across dis-
eases or conditions, they may have chosen generic
measures that cover all relevant areas of HRQoL (in-
cluding, for example, self-care, and physical, emotional,
and social function), and are designed for administration
to people with any kind of underlying health problems
(or no problem at all). These instruments are sometimes
called health profiles; the most popular health profiles
are short forms of the instruments used in the Medical
Outcomes Study, such as SF-36 and SF-12 [14-16]. Al-
ternatively (or in addition) RCTs may have relied on
Table 2 A taxonomy of health status and quality of life measures [13]
Measure Strengths Weaknesses
Types of Scores Produced
Single indicator number Global evaluation May be difficult to interpret
Useful for population
Single index number Represents net impact Sometimes not possible to disaggregate contribution of
domains to the overall score
Useful for cost effectiveness
Profile of interrelated scores Single instrument Length may be a problem
Contribution of domains to
overall score possible
May not have overall score
Battery of independent scores Wide range of relevant
outcomes possible
Cannot relate different outcomes to common
measurement scale
May need to adjust for multiple comparisons
May need to identify the major outcome
Range of Populations and Concepts
Generic: applied across diseases, conditions, populations,
and concepts
Broadly applicable May not be responsive to change
Summarizes range of concepts May not have focus of patient interest
Detection of unanticipated
effects possible
Length may be a problem
Effects may be difficult to interpret
Specific: applied to individuals, diseases, conditions,
populations, or concepts/domains
More acceptable to respondents Cannot compare across conditions or populations
May be more responsive to
change
Cannot detect unanticipated effects
Weighting System
Utility: preference weights from patients, providers, or
community
Interval scale May have difficulty obtaining weights
Patient or consumer view
incorporated
May not differ from statistical weights that are easier to
obtain
Equal-weighting: items weighted equally or from
frequency or responses
Self-weighting samples May be influenced by prevalence
More familiar techniques Cannot incorporate tradeoffs
Appears easier to use
*Adapted from Patrick and Erickson, 1993.
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sexual function), a problem (e.g. pain), or a disease (e.g.
heart failure, asthma, or cancer).
Another issue to consider is how the instruments are
weighted. By convention, many specific instruments
weight items equally because the scoring of multi-item
scales is usually based on the average of component
items. Utility instruments designed for economic ana-
lysis put greater emphasis on item weighting, attempting
to ultimately present HRQoL as a continuum anchored
between death and full health. Readers interested in a
summary of these issues can look to an old, but still use-
ful summary [17].
Assessment of quality of evidence specific to
PROs
Investigators use many instruments to capture PROs,
and methods for developing, validating, and analyzing
PRO data are diverse. In producing their SoF table, we
suggest reviewers use the GRADE approach thatidentifies eight factors that influence confidence in an
estimate of effect. While a body of evidence from RCTs
starts at high quality, they may be assigned a lower rat-
ing because of risk of bias, imprecision, indirectness, in-
consistency, or a high likelihood of publication bias. A
body of evidence for an outcome from observational
studies starts at low quality; factors that can increase
confidence in estimates of effect are: large magnitude of
effect, all plausible confounding would reduce the dem-
onstrated effect (or increase the effect if no effect was
observed) and a dose-response gradient. Figure 2 out-
lines the key factors for the assessment of the overall
quality of evidence for a particular outcome.
Issues of particular relevance to PROs include prob-
lems in the validity of the instruments use (e.g., without
extensive patient input, items and domains may not be
both important to the target population and comprehen-
sive with respect to patient concerns, and if not properly
developed, instruments may not actually reflect the
intended constructs), and issues of interpretability of
Figure 2 GRADE’s approach to rating quality of evidence (aka confidence in effect estimates).
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represents small, medium, and large differences in
HRQoL). Table 1 outlines the key issues in describing
and assessing PROs.Validity
Validity has to do with whether the instrument is meas-
uring what it is intended to measure. Content validity
assessment involves patient and clinician evaluation of
the importance and completeness of the content
contained in the measures, usually obtained through
qualitative research [18,19]. Construct validity is based
on validation strategies developed by psychologists, who
for many years have struggled with determining whether
questionnaires assessing intelligence and attitudes really
measure what is intended. Construct validity involves
examining the logical relationships that should exist be-
tween assessment measures. For example, we would ex-
pect that patients with lower treadmill exercise capacity
generally will have more dyspnea in daily life than those
with higher exercise capacity, and we would expect to
see substantial correlations between a new measure of
emotional function and existing emotional function
questionnaires. In rare cases, criterion validity may exist
where there is a gold standard for self-report, usually a
longer version of the instrument of interest.
When we are interested in evaluating change over
time, we examine correlations of change scores. For ex-
ample, patients who deteriorate in their treadmill exer-
cise capacity should, in general, show increases in
dyspnea, whereas those whose exercise capacity im-
proves should experience less dyspnea; a new emotional
function measure should show improvement in patients
who improve on existing measures of emotionalfunction. The technical term for this process is testing
an instrument’s construct (or concurrent) validity.
Reviewers should look for evidence of the validity of
PROs used in clinical studies. Unfortunately, reports of
RCTs using PROs seldom review evidence of the validity
of the instruments they use, but when available re-
viewers can gain some reassurance from statements
(backed by citations) that the questionnaires have been
previously validated.
A final concern about validity arises if the measure-
ment instrument is used with a different population, or
in a culturally and linguistically different environment
than the one in which it was developed – typically, use
of a non-English version of an English-language ques-
tionnaire. Ideally, one would have evidence of validity in
the population enrolled in the RCT. PRO measures
should, ideally, be re-validated in each study using what-
ever data are available for the validation: for instance,
the relation between the PRO and other related out-
comes measured. In the absence of empirical evidence of
validity, reviewers are entitled to skepticism about the
study’s PROs and may consider rating down the overall
confidence in estimates on this basis [9].Responsiveness or ability to detect change
When we use instruments to evaluate treatment effects,
they must be able to measure differences between
groups, if differences do in fact exist. Randomization
should ensure that patients in the intervention and con-
trol groups begin studies with the same status on what-
ever concept or construct the PRO is designed to
measure. PROs must be able to distinguish among pa-
tients who remain the same, improve, or deteriorate over
the course of the trial. This is sometimes referred to as
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change.
An instrument with a poor ability to measure change
can result in false-negative results in which the interven-
tion improves how patients feel, yet the instrument fails
to detect the improvement. This problem may be par-
ticularly salient for generic questionnaires that have the
advantage of covering all relevant areas of HRQoL, but
the disadvantage of covering each area superficially [20].
In studies that show no difference in PROs between
intervention and control, lack of instrument responsive-
ness is one possible reason. Suspicion about lack of abil-
ity to measure change is another potential reason for
rating down the quality of evidence from a series of
RCTs [9].Reporting bias
Studies focusing on PROs often use a number of instru-
ments to measure the same, or similar constructs. This
situation creates a risk of reporting bias. It is possible for
investigators to measure a number of outcomes, and
only report those that showed significant effects. Meth-
odologists have long suspected the existence of outcome
reporting bias [21,22], and systematic investigations
comparing RCT protocols and their subsequent publica-
tions have provided estimates of its magnitude [23-25].
Investigators have examined a random sample of 156
completed Cochrane reviews that included 10 or more
studies [26]. They found that a median of 46% of the re-
view’s eligible trials (IQR: 20 to 75%, range: 2 to 100%)
contributed to the pooled estimates. Thus, approxi-
mately half of the RCTs identified by the Cochrane re-
views did not contribute to the pooled effect size in their
meta-analyses. Furthermore, they found a correlation be-
tween effect size and the number of studies included
(the fewer the studies, the larger the effect size) and this
effect appeared strongest in studies using continuous
outcomes (the correlation between the percentage of tri-
als included in a meta-analysis and the SMD was -0.18
(95% CI: -0.35 to -0.01, p = 0.04). When analyses in-
cluded less than 20% of eligible studies the mean effect
size was 0.64 and when they included over 80% of the
eligible studies the mean effect size was 0.31.
These results demonstrate just how frequently studies
fail to provide data for meta-analyses, and provide sup-
port for the existence of reporting bias in which investi-
gators are inclined to selectively report results with
larger effects. Systematic reviews focusing on PROs
should be alert to this problem. When only a small
number of eligible studies have reported a particular
outcome, particularly if it is a salient outcome that one
would expect conscientious investigators to measure, re-
viewers should note the possibility of reporting bias andconsider rating down confidence in estimates of effect in
their summary of findings table [27].
Outcome characteristics
Deciding how to pool across studies
The definition of a particular PRO may vary between
studies, and this may justify use of different instruments.
Even if the definitions are similar (or if, as happens more
commonly, the investigators do not define the PRO), the
investigators may choose different instruments to meas-
ure the PRO. For example, the following instruments are
all validated patient-reported pain instruments that an
investigator may use in a primary study to assess an in-
tervention’s usefulness for treating pain: the 20-item Mc-
Gill Pain Questionnaire, the 7-item Integrated Pain
Score, and the 56-item Brief Pain Inventory [28].
When deciding if statistical pooling is appropriate, re-
viewers will often find themselves reading between the
lines to try and get a precise notion of the concepts or
constructs underlying PROs. They may have to make at
least a brief foray into the articles that describe the de-
velopment and prior use of PRO instruments included
in the primary studies. For example, authors of a
Cochrane review of cognitive behavioural therapy (CBT)
for tinnitus included QoL as an outcome [29], which
was assessed in four trials using the Tinnitus Handicap
Questionnaire, in one trial the Tinnitus Questionnaire,
and in one trial the Tinnitus Reaction Questionnaire.
The original sources are cited in the review. Information
on the items and the concepts measured are contained
in the cited articles, and review authors were able to
compare the content of the instruments and conclude
that statistical pooling was appropriate.
Systematic reviewers must decide how to categorize
PROs and when to pool results. These decisions will be
based on the characteristics of the PRO, which will need
to be extracted and reported in the review. On most oc-
casions, studies using PROs will make baseline and
follow-up measurements and the outcome of interest
will thus be the difference in change from baseline to
follow-up between intervention and control groups.
Ideally then, to pool data across two PROs that are con-
ceptually related, one will have evidence of convincing
longitudinal correlations of change in the two measures in
individual patient data, and evidence of similar responsive-
ness of the instruments. Further supportive evidence
could come from correlations of differences between
treatment and control, or difference between before and
after measurements, across studies. If one cannot find any
of these data, one could fall back on cross-sectional corre-
lations in individual patients at a point in time.
For example, the two major instruments used to meas-
ure HRQoL in patients with chronic obstructive disease
are the Chronic Respiratory Questionnaire (CRQ) and
Johnston et al. Health and Quality of Life Outcomes 2013, 11:109 Page 8 of 10
http://www.hqlo.com/content/11/1/109the St. George’s Respiratory Questionnaire (SGRQ). Cor-
relations between the two questionnaires in individual
studies have varied from 0.3 to 0.6 in both cross-
sectional (correlations at a point in time) and longitu-
dinal (correlations of change) comparisons [30-32]. In a
subsequent investigation, investigators examined the
correlations between changes in the CRQ and SGRQ in
15 studies including 23 patient groups and found a cor-
relation of 0.88 [33]. Despite this extremely strong cor-
relation, the CRQ proved more responsive than the
SGRQ: standardized response means of the CRQ (median
0.51, IQR 0.19-0.98) were significantly higher (p < 0.001)
than those associated with the SGRQ (median 0.26, IQR -
0.03-0.40). As a result, pooling results from trials using
these two instruments could lead to underestimates of
treatment effect in studies using the SGRQ [33-35].
Most of the time, unfortunately, detailed data such as
those described in the previous paragraph will be un-
available. Investigators must then fall back on intuitive
decisions about the extent to which different instru-
ments are measuring the same underlying concept. For
example, the authors of a meta-analysis of psychosocial
interventions in the treatment of pre-menstrual syn-
drome faced a profusion of outcome measures, with 25
PROs reported in their nine eligible studies [36]. They
dealt with this problem by having two experienced clin-
ical researchers, knowledgeable to the study area and
not otherwise involved in the review, independently
examine each instrument - including all domains - and
group 16 PROs into 6 discrete conceptual categories.
Any discrepancies were resolved by discussion to achieve
consensus. The pooled analysis of each category included
between 2 to 6 studies. The ‘List of combinable instru-
ments measuring similar constructs’ details the categories
and the included instruments within each category.




Menstrual Symptom Diary - Anxiety domain
State and Trait Anxiety Scale-State Anxiety domain
Behavioural Changes
Menstrual Distress Questionnaire-Behavioural Changes
domain
Pre-Menstrual Assessment Form-Social Withdrawal
domain
Depression
Beck Depression InventoryDepression Adjective Checklist State-Depression
domain
General Contentment Scale - Depression and Well-
being domain
Menstrual Symptom Diary-Depression domain
Menstrual Distress Questionnaire-Negative Affect
domain
Interference
Global Rating of Interference Daily Record of
Menstrual Complaints – Interference domain
Sexual Relations
Martial Satisfaction Inventory-Sexual Dissatisfaction
domain
Social Adjustment Scale - Sexual Relationship domain
Water Retention and Edema
Menstrual Distress Questionnaire-Water Retention
domain
Menstrual Symptom Diary-Edema domain
Summary
We have suggested a step-by-step approach to address-
ing issues of PROs in meta-analyses. This guidance on
PROs and why they are important for health care
decision-making, including the key risk of bias issues
that reviewers should consider when combining PROs in
meta-analysis is likely to enhance the usefulness of such
overviews to end-users. In part 2 of this series, we will
provide an overview of available methods for improving
the interpretability of pooled estimates of PROs.
Nomenclature
PROs, patient-reported outcomes
RCTs, randomized controlled trials
FDA, Food and Drug Administration
HRQoL, health-related quality of life
BPQ, Breathing Problems Questionnaire
FEV1, forced expiratory volume
QoL, quality of life
SoF, Summary of Findings
IQR, interquartile range
CI, confidence interval
SMD, standardized mean difference
CBT, cognitive behavioural therapy
CRQ, Chronic Respiratory Questionnaire
SGRQ, St. George's Respiratory Questionnaire
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